PEspeaks

Dec 21, 2017
Pharmaceutical Executive
While pricing issues need to be addressed in a transparent manner, what cannot be disputed is that the vast majority of the industry is committed to the discovery of vital new medicines with the power to change patients’ lives, writes Dr Steve Arlington.
Dec 20, 2017
Pharmaceutical Executive
In the search for effective and efficient ways to bridge the urban/rural divide, technological advances are offering more and more solutions.
Dec 19, 2017
Consumers of life sciences products are reluctant customers, and this reluctance can turn into non-compliance. Companies and providers need to understand patients at a human level, and what will motivate them to stay with a treatment plan.
Dec 18, 2017
Pharmaceutical Executive
With over 70 companies manufacturing immediate-release opioids in the United States, federal regulators may look to limit marketing to reduce the prescription and over-prescription of opioids.
Dec 11, 2017
Pharmaceutical Executive
In 2017, patients gained access to the first gene therapies and more orphan and breakthrough drugs.
Dec 10, 2017
Pharmaceutical Executive
New action plan urges tighter alignment of public health policy with the development of targeted therapies.
Dec 06, 2017
Bagrat Lalayan presents an overview of osteoporosis treatment market and offers vision for future business strategies.
Dec 05, 2017
Pharmaceutical Executive
Innovation by itself won't solve the complex multichannel challenges pharmas face. Jeff Greene reports.
Nov 30, 2017
Experts slam drug prices and endorse government price negotiations and curbs on drug advertising.
Nov 22, 2017
Jill Wechsler discusses the hot topic of how FDA should oversee combination products that incorporate a digital health component.
native1_300x100
lorem ipsum